FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - November 13, 2024 610 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved the VENTANA CLDN18 (43-14A) RxDx Assay as a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Promising Signal of Efficacy for Adjuvant Nivolumab in Patients with Completely... July 19, 2023 FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma July 31, 2020 Speaking with One Cancer Voice for cancer patients in England March 29, 2023 Man Gives Up His First-Class Seat For 88-Year-Old Woman, Makes Her... November 16, 2021 Load more HOT NEWS Activity and Safety of Atezolizumab Combined with Carboplatin and Pemetrexed in... The team of over 60 scientists investigating the age-old mystery of... Darolutamide Delays the Spread of Some Prostate Cancers FDA Approves Teclistamab in Combination with Daratumumab Hyaluronidase-fihj for Relapsed or...
